Johns Hopkins Researchers Identify Prostate Cell Population

A specific basal cell type found in the prostate transition zone may explain why glands enlarge as men age.

Updated on Oct. 25, 2026 in Men’s Health

Isometric editorial illustration of a stylized prostate tissue cross-section with distinct hexagonal cell clusters in muted oxblood and teal. — Johns Hopkins researchers have identified a distinct population of WIF1+ basal cells in the prostate transition zone, potentially explaining age-related gland enlargement. AI Illustration. Upload story photo >

Live Poll

Are you confident that new scientific discoveries will lead to better treatments for age-related health issues?

Researchers at Johns Hopkins University have identified a distinct population of WIF1+ basal cells in the transition zone of the human prostate. These cells are anatomically unique and may play a direct role in the development of benign prostatic hyperplasia.

Why it matters

Understanding the specific cellular origins of prostate enlargement could provide critical insight into why the transition zone is uniquely susceptible to growth. This discovery offers a potential new avenue for targeted medical interventions in men's health.

The study utilized single-cell RNA sequencing to analyze nearly 130,000 individual prostate cells from 10 tissue samples. These cells were categorized to map the unique transcriptional signatures found specifically in the gland's transition zone.

The players

Johns Hopkins University

This major research institution based in Baltimore led the prostate cell study.

Charles Welliver

He is a urologist affiliated with Albany Medical College who has provided expert commentary on prostate health.

The details

The team examined noncancerous tissue samples from the three major zones of the prostate to differentiate between common cell types and the identified WIF1+ population. The study, published in The Journal of Pathology, confirms these cells are anatomically and transcriptionally distinct from other basal cell groups.

October 25, 2026: The research findings were published in The Journal of Pathology.
August 2026: Urologist Charles Welliver discussed benign prostatic hyperplasia on a podcast.

The Big Picture

This study follows a pattern set by the Johns Hopkins prostate transition zone mapping program, which seeks to decode localized tissue growth. It marks a departure from legacy models that treated all basal cells as uniform populations across the entire gland.

This discovery could lead to future drug targets for benign prostatic hyperplasia, potentially offering more precise treatment options than current systemic medications. Patients may eventually see these findings inform new clinical protocols for managing prostate enlargement.

The takeaway

Future studies will aim to determine the functional roles these cells play in the actual expansion of the prostate gland. Identifying these targets early may assist in developing non-surgical therapies for men experiencing common prostate enlargement issues.